As an alternative, drugs with DNMT inhibitory activity that have been approved by the Food and Drug Administration (FDA) for other indications, such as the antihypertensive, antiarrhythmic medicines hydralazine and procainamide [156,157], are being investigated for their potential impact on treating obesity and diabetes (NCT00000620, NCT02046395; https://clinicaltrials.gov/; accessed on 14 January 2022). Here, DNMT1 is linked to Obesity.